We are live on ! Find out more
ACOR

Acorda Therapeutics
ACOR

Delisted

ACOR was delisted on the 11th of April, 2024.

Back to rankings

47 hedge funds and large institutions have $11.8M invested in Acorda Therapeutics in 2020 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 8 increasing their positions, 15 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

122% more call options, than puts

Call options by funds: $226K | Put options by funds: $102K

19% more capital invested

Capital invested by funds: $9.86M → $11.8M (+$1.92M)

22% less funds holding

Funds holding: 60 → 47 (-13)

47% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 15

59% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 22

Holders
47
Holders Change
-13
Holders Change %
-21.67%
% of All Funds
0.83%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
8
Reduced
15
Closed
22
Calls
$226K
Puts
$102K
Net Calls
+$124K
Net Calls Change
+$814K

Top Buyers

1
Renaissance Technologies
Renaissance Technologies
New York
+$190K
2
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$166K
3
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$149K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$114K
5
Group One Trading
Group One Trading
Illinois
+$90.5K

Top Sellers

1
Point72 Asset Management
Point72 Asset Management
Connecticut
-$840K
2
Parallax Volatility Advisers
Parallax Volatility Advisers
California
-$829K
3
Vanguard Group
Vanguard Group
Pennsylvania
-$799K
4
GCP
GSA Capital Partners
United Kingdom
-$346K
5
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
-$222K
Name Holding Trade Value Shares
Change 		Change in
Stake
SEI Investments
51
SEI Investments
Pennsylvania
– -$37K -605 Closed
Goldman Sachs
52
Goldman Sachs
New York
– -$36K -583 Closed
Russell Investments Group
53
Russell Investments Group
United Kingdom
– -$31K -510 Closed
Ameriprise
54
Ameriprise
Minnesota
– -$27K -439 Closed
Millennium Management
55
Millennium Management
New York
– -$16 -264 Closed
SBIA
56
Sheaff Brock Investment Advisors
Indiana
– -$13K -208 Closed
SG Americas Securities
57
SG Americas Securities
New York
– -$13K -204 Closed
LP
58
LMR Partners
United Kingdom
– -$9K -139 Closed
WS
59
Wedbush Securities
California
– -$8K -126 Closed
HB
60
Homrich & Berg
Georgia
– -$8K -125 Closed
GWM
61
Geneos Wealth Management
Colorado
– -$6K -83 Closed
BNP Paribas Financial Markets
62
BNP Paribas Financial Markets
France
– -$4.01K -65 Closed
JP Morgan Chase
63
JP Morgan Chase
New York
– -$1.93K -21 Closed
FWM
64
Focused Wealth Management
New York
– -$1K -8 Closed
SFS
65
Sowell Financial Services
Arkansas
– +$368 +4 New
HS
66
Horan Securities
United States
– +$552 +6 New
1 2
3

ACOR Hedge Fund Activity: Q4 2020 in Review

47 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Acorda Therapeutics (ACOR) for Q4 2020, worth a combined $11.8M — up 19% from $9.86M a quarter earlier.

Sellers outnumbered buyers: 22 funds closed out of ACOR and 9 opened new positions — a net loss of 13 holders — while 15 trimmed existing stakes and 8 added.

The largest buyer was Renaissance Technologies, adding an estimated $190K. The largest seller was Point72 Asset Management, cutting an estimated $840K.

  • 47 institutional investors held Acorda Therapeutics (ACOR) as of Q4 2020, down from 60 in Q3 2020.
  • Funds reported $11.8M of Acorda Therapeutics stock for Q4 2020, up 19% quarter-over-quarter.
  • 9 funds opened new Acorda Therapeutics positions in Q4 2020 and 22 closed out, a net change of -13 holders.
  • The largest Acorda Therapeutics buyer in Q4 2020 was Renaissance Technologies, an estimated $190K added.
  • The largest Acorda Therapeutics seller in Q4 2020 was Point72 Asset Management, an estimated $840K sold.

Based on aggregated 13F filings for Q4 2020.